Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2 Study to Evaluate the Efficacy and Safety of UI030 in COVID-19 Patients

NCT05055414 is registered in ClinicalTrials.gov with Korea United Pharm. Inc. as lead sponsor.

NCT NCT05055414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05055414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2 Study to Evaluate the Efficacy and Safety of UI030 in COVID-19 Patients
Lead sponsor
Korea United Pharm. Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2021
Completion date
November 1, 2022
Enrollment
140 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infection